KUALA LUMPUR, Jan 20 (Bernama) -- BiomeBank has announced Chris Hall as the new Chair for the clinical stage biotechnology company, with the appointment effective Jan 17.
Having recently served as Chief Investment Officer of Ellerston Capital, prior to this, Hall served as Managing Director of BlackRock Asset Management (North-Asia Ltd).
He succeeds Dr Stephen Rodda, who recently retired having served as the BiomeBank Chair since 2019, according to a statement.
BiomeBank Chief Executive Officer, Thomas Mitchell said: “We're thrilled to welcome Hall as the new Chair of BiomeBank. He brings with him over 30 years' experience and an impressive track record of investment management across both public and private markets within the APAC region.
“As we move towards closing our Series A funding round in early 2022 and formal TGA approval of our first-generation product, Hall's experience in global markets will support our growth ambition into the Asia Pacific and European region.”
Meanwhile, the newly-elected BiomeBank Chair, Hall said: “I'm excited to join BiomeBank as we move into the next stage of expansion and progress our promising pipeline of second-generation products.
“Having observed the Company's expertise in developing microbial therapies to treat unmet need, I believe we're in a strong position to improve the quality of life for people and continue to build our business into a global biotechnology leader.”
Backed by a world-leading team of translational microbiome experts, BiomeBank's platform uses a unique combination of machine learning and microbiology to identify bacterial strains which influence disease, leading to the discovery and development of new therapies.
-- BERNAMA
No comments:
Post a Comment